Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
ZYBAN is an oral extended-release tablet approved in 1997 for smoking cessation, representing a non-nicotine pharmacological intervention in the addiction treatment space. The exact mechanism of action is not publicly detailed in this dataset, but the product operates as a small-molecule therapeutic. It is a foundational product in the smoking cessation market with decades of clinical use.
As a mature product approaching loss of exclusivity with moderate competitive pressure (30/100), the brand team is likely focused on retention and lifecycle extension rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A 7-year Assessment on Subject Understanding of ZYBAN/ WELLBUTRIN Associated Risks
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation
Worked on ZYBAN at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Zero linked job openings indicate minimal active hiring for this product, reflecting its LOE-approaching lifecycle stage. Career opportunities are limited primarily to defensive commercial strategies focused on market retention and lifecycle management rather than growth initiatives.